利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

14 条记录 (耗时 0.027 秒)

    2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
    6.
    发明申请
    2-(Pyridin-3-ylamino)-pyrido[2,3-D]pyrimidin-7-ones 审中-公开
    2-（吡啶-3-基氨基） - 吡啶并[2,3-D]嘧啶-7-酮

    公开(公告)号：US20050182078A1

    公开(公告)日：2005-08-18

    申请号：US11060015

    申请日：2005-02-16

    申请人： Mark Barvian ,  Peter Toogood ,  Scott VanderWel

    发明人： Mark Barvian ,  Peter Toogood ,  Scott VanderWel

    IPC分类号： A61K31/519 ,  C07D213/74 ,  C07D471/04 ,  C07D487/02

    CPC分类号： C07D213/74 ,  C07D471/04

    摘要： This invention provides compounds of formula I: wherein R1, R2, R3, R4, and X1 are as defined in the specification. The 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-one compounds of formula I, which are inhibitors of cyclin-dependent kinases 2 and 4 (CDK2 and CDK4), are useful in treating cell proliferative disorders.

    摘要翻译： 本发明提供式I化合物：其中R 1，R 2，R 3，R 4和R 4， X 1如本说明书中所定义。 作为细胞周期蛋白依赖性激酶2和4（CDK2和CDK4）的抑制剂的式I的2-（吡啶-3-基氨基） - 吡啶并[2,3-d]嘧啶-7-酮化合物可用于治疗 细胞增殖障碍。

    PTERIDINONES AS KINASE INHIBITORS
    7.
    发明申请
    PTERIDINONES AS KINASE INHIBITORS 审中-公开
    西替尼嗪作为激酶抑制剂

    公开(公告)号：US20070049600A1

    公开(公告)日：2007-03-01

    申请号：US11553935

    申请日：2006-10-27

    申请人： William Denny ,  Gordon Rewcastle ,  Ellen Dobrusin ,  James Kramer ,  Dennis McNamara ,  Howard Daniel Showalter ,  Peter Toogood

    发明人： William Denny ,  Gordon Rewcastle ,  Ellen Dobrusin ,  James Kramer ,  Dennis McNamara ,  Howard Daniel Showalter ,  Peter Toogood

    IPC分类号： C07D475/02 ,  A61K31/525

    CPC分类号： C07D475/00

    摘要： Disclosed are compounds of the formula wherein: W is NH, S, SO, or SO2; R2 is (un)substituted aryl, (un)substituted heteroaryl, or (un)substituted carbocycle or heterocycle; Q is hydrogen or lower alkyl; R4 and R6 are the same or different and represent hydrogen, halogen, lower alkyl, lower alkoxy, (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl; and R8 is hydrogen, lower alkyl or an (un)substituted carbocyclic group containing from 3-7 members, up to two of which members are optionally hetero atoms selected from oxygen and nitrogen; or R8 is (un)substituted aryl, (un)substituted heteroaryl, (un)substituted arylalkyl or (un)substituted heteroarylalkyl. These compounds are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases. The present invention also provides a method of treating cell proliferative disorders. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.

    摘要翻译： 公开了下式的化合物其中：W是NH，S，SO或SO 2; R 2是（未）取代的芳基，（未）取代的杂芳基或（取代的）取代的碳环或杂环; Q是氢或低级烷基; R 4和R 6相同或不同，表示氢，卤素，低级烷基，低级烷氧基，（未）取代的芳基，（未）取代的杂芳基，（un ）取代的芳基烷基或（未）取代的杂芳基烷基; 和R 8是氢，低级烷基或含有3-7个成员的（未）取代的碳环，其中至多两个成员任选是选自氧和氮的杂原子; 或（R 8）是（un）取代的芳基，（未）取代的杂芳基，（未）取代的芳基烷基或（未）取代的杂芳基烷基。 这些化合物可用于治疗细胞增殖性疾病，如癌症和再狭窄。 这些化合物是细胞周期蛋白依赖性激酶（cdks）和生长因子介导的激酶的有效抑制剂。 本发明还提供了治疗细胞增殖性疾病的方法。 本发明还提供了含有式I化合物的药学上可接受的组合物。